{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:12:48Z","timestamp":1787015568941,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,4,19]],"date-time":"2014-04-19T00:00:00Z","timestamp":1397865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["DA031883"],"award-info":[{"award-number":["DA031883"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["DA000378"],"award-info":[{"award-number":["DA000378"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2014,8]]},"abstract":"Abstract<\/jats:title>\n \n Mephedrone (4\u2010methylmethcathinone) is a synthetic cathinone designer drug that alters pre\u2010synaptic dopamine (\n DA<\/jats:styled-content>\n ) activity like many psychostimulants. However, little is known about the post\u2010synaptic dopaminergic impacts of mephedrone. The neuropeptide neurotensin (\n NT<\/jats:styled-content>\n ) provides inhibitory feedback for basal ganglia and limbic\n DA<\/jats:styled-content>\n pathways, and post\u2010synaptic D\n 1<\/jats:sub>\n \u2010like and D\n 2<\/jats:sub>\n \u2010like receptor activity affects\n NT<\/jats:styled-content>\n tissue levels. This study evaluated how mephedrone alters basal ganglia and limbic system\n NT<\/jats:styled-content>\n content and the role of\n NT<\/jats:styled-content>\n receptor activation in drug consumption behavior. Four 25\u00a0mg\/kg injections of mephedrone increased\n NT<\/jats:styled-content>\n content in basal ganglia (striatum, substantia nigra and globus pallidus) and the limbic regions (nucleus accumbens core), while a lower dosage (5\u00a0mg\/kg\/injection) only increased striatal\n NT<\/jats:styled-content>\n content. Mephedrone\u2010induced increases in basal ganglia\n NT<\/jats:styled-content>\n levels were mediated by D\n 1<\/jats:sub>\n \u2010like receptors in the striatum and the substantia nigra by both D\n 1<\/jats:sub>\n \u2010like and D\n 2<\/jats:sub>\n \u2010like receptors in the globus pallidus. Mephedrone increased substance P content, another neuropeptide, in the globus pallidus, but not in the dorsal striatum or substantia nigra. Finally, the\n NT<\/jats:styled-content>\n receptor agonist\n PD<\/jats:styled-content>\n 149163 blocked mephedrone self\u2010administration, suggesting reduced\n NT<\/jats:styled-content>\n release, as indicated by increased tissue levels, likely contributing to patterns of mephedrone consumption.\n \n \n image<\/jats:alt-text>\n <\/jats:graphic>\n <\/jats:boxed-text>\n <\/jats:p>\n This study evaluated the effects of mephedrone upon the neuropeptide neurotensin (NT) \u2013 an inhibitory feedback of dopamine signaling \u2013 within the basal ganglia and limbic system of the central nervous system as well as the role of NT in mephedrone self\u2010administration. Mephedrone increased NT tissue content, which corresponds to reduced NT release and signaling, and NT receptor agonist treatment reduces mephedrone self\u2010administration, suggesting drug consumption behavior may be tied to the loss of NT signaling.<\/jats:p>","DOI":"10.1111\/jnc.12727","type":"journal-article","created":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T18:10:16Z","timestamp":1396030216000},"page":"402-407","source":"Crossref","is-referenced-by-count":7,"title":["Mephedrone alters basal ganglia and limbic neurotensin systems"],"prefix":"10.1111","volume":"130","author":[{"given":"Christopher L.","family":"German","sequence":"first","affiliation":[{"name":"Department of Pharmacology & Toxicology College of Pharmacy University of Utah Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda H.","family":"Hoonakker","sequence":"additional","affiliation":[{"name":"School of Dentistry and Department of Pharmacology & Toxicology College of Pharmacy University of Utah Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette E.","family":"Fleckenstein","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Toxicology College of Pharmacy University of Utah Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen R.","family":"Hanson","sequence":"additional","affiliation":[{"name":"School of Dentistry and Department of Pharmacology & Toxicology College of Pharmacy University of Utah Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,19]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"193","volume-title":"Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances","author":"Addiction","year":"2011"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-008-1316-3"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2011.07215.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.304"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0031-6997(24)01509-6","article-title":"Neurotensin and dopamine interactions","volume":"53","author":"Binder E. B.","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90021-3"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2004.06.061"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000668"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1523\/JNEUROSCI.18-17-06977.1998","article-title":"The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: functional evidence for a pallidal glutamate\u2010GABA interaction via the pallidal\u2010subthalamic nucleus loop","volume":"18","author":"Ferraro L.","year":"1998","journal-title":"J. Neurosci."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.47.120505.105140"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.08.036"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2013.07.023"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0022-3565(25)22337-0","article-title":"Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions","volume":"270","author":"Gygi S. P.","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.184119"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2011.12.037"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0022-5347(25)00293-9","article-title":"Effect of methamphetamine on neurotensin concentrations in rat brain regions","volume":"241","author":"Letter A. A.","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.01998.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90098-8"},{"key":"e_1_2_7_20_1","first-page":"10","volume-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos G.","year":"1986"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(85)91542-2"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(81)90053-X"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02145.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)91343-9"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjnc.12727","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjnc.12727","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jnc.12727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T01:54:59Z","timestamp":1746150899000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jnc.12727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,19]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/jnc.12727"],"URL":"https:\/\/doi.org\/10.1111\/jnc.12727","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,19]]}}}